ImClone Investigational Site

Boston, Massachusetts 02215

0 studies enrolling now · 12 studies all time

What they study most

Adenocarcinoma, Colorectal Cancer, Colorectal Neoplasms, Fallopian Tube Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor (GIST), Head and Neck Cancer, Hepatocellular Carcinoma, Malignant Melanoma, Metastases, Metastatic Renal Cell Carcinoma, Neoplasm

Studies at this site

• Study of Ramucirumab in Ovarian Cancer — Completed
• A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer — Completed
• Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma — Completed
• An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma — Completed
• Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck — Completed
• A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors — Stopped early
• A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib — Completed
• Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy — Completed
• A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma — Completed
• Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy — Completed
• Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer — Completed
• Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer — Completed